Table of Content

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 STUDY SCOPE 31
1.3.1 SEGMENTS CONSIDERED 31
1.3.2 INCLUSIONS AND EXCLUSIONS 32
1.3.3 YEARS CONSIDERED 32
1.3.4 CURRENCY CONSIDERED 32
1.4 STAKEHOLDERS 33
1.5 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.2 RESEARCH APPROACH 34
2.2.1 SECONDARY DATA 35
2.2.1.1 Key data from secondary sources 35
2.2.1.2 Objectives of secondary research 35
2.2.2 PRIMARY DATA 36
2.2.2.1 Objectives of primary research 36
2.2.2.2 Key data from primary sources 37
2.2.2.3 Key industry insights 38
2.2.2.4 Breakdown of primaries 38
2.3 MARKET SIZE ESTIMATION 39
2.3.1 BOTTOM-UP APPROACH 39
2.3.1.1 Company revenue estimation approach 40
2.3.1.2 Company presentations and primary interviews 40
2.3.1.3 Growth forecasts 40
2.3.1.4 CAGR projections 41
2.3.2 TOP-DOWN APPROACH 41
2.4 DATA TRIANGULATION 42
2.5 STUDY ASSUMPTIONS 43
2.6 RESEARCH LIMITATIONS 43
2.7 RISK ASSESSMENT 44
3 EXECUTIVE SUMMARY 45
?
4 PREMIUM INSIGHTS 49
4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW 49
4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2024 VS. 2029 49
4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2024 VS. 2029 50
4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2024 VS. 2029 50
4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2024 VS. 2029 51
4.6 CLINICAL TRIAL IMAGING MARKET: REGIONAL GROWTH OPPORTUNITIES 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
5.2.1 DRIVERS 52
5.2.1.1 Increasing R&D spending in pharmaceutical and biotechnology companies 52
5.2.1.2 Rising number of clinical trials in medical research 53
5.2.1.3 Growth in pharmaceutical and biotechnology industries 54
5.2.1.4 Increasing number of contract research organizations 54
5.2.2 RESTRAINTS 54
5.2.2.1 High implementation cost of imaging systems 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Growth opportunities in emerging economies 55
5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals 55
5.2.4 CHALLENGES 55
5.2.4.1 High cost of clinical trials 55
5.3 PRICING ANALYSIS 56
5.3.1 INDICATIVE PRICING ANALYSIS FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021–2023 56
5.4 PATENT ANALYSIS 57
5.4.1 LIST OF MAJOR PATENTS, 2022–2023 57
5.5 TRADE ANALYSIS 58
5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUS (HS CODE 9022) 58
5.5.1.1 Import data for X-ray apparatus 58
5.5.1.2 Export data for X-ray apparatus 59
5.5.2 TRADE ANALYSIS FOR CT APPARATUS (HS CODE 902212) 59
5.5.2.1 Import data for CT apparatus 59
5.5.2.2 Export data for CT apparatus 60
5.6 VALUE CHAIN ANALYSIS 60
5.7 SUPPLY CHAIN ANALYSIS 61
5.8 ECOSYSTEM ANALYSIS 62
5.8.1 ROLE IN ECOSYSTEM 62
?
5.9 PORTER’S FIVE FORCES ANALYSIS 63
5.9.1 THREAT OF NEW ENTRANTS 64
5.9.2 THREAT OF SUBSTITUTES 64
5.9.3 BARGAINING POWER OF BUYERS 64
5.9.4 BARGAINING POWER OF SUPPLIERS 64
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 65
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 65
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 65
5.10.2 KEY BUYING CRITERIA 66
5.11 REGULATORY ANALYSIS 67
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 71
5.13 TECHNOLOGY ANALYSIS 72
5.13.1 KEY TECHNOLOGIES 72
5.13.1.1 CT and MRI 72
5.13.2 COMPLEMENTARY TECHNOLOGIES 72
5.13.2.1 Ultrasound 72
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 73
5.15 CASE STUDY ANALYSIS 73
5.15.1 REVIEW OF CT FINDINGS AND HISTOPATHOLOGICAL CHARACTERISTICS OF PRIMARY LIVER CARCINOSARCOMA 73
5.16 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL IMAGING MARKET 74
6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 76
6.1 INTRODUCTION 77
6.2 SERVICES 77
6.2.1 OPERATIONAL IMAGING SERVICES 79
6.2.1.1 Rising number of CROs and growing pharmaceutical industry to drive market 79
6.2.2 READ ANALYSIS SERVICES 81
6.2.2.1 Increasing number of clinical trials and rising R&D spending to support market growth 81
6.2.3 SYSTEM AND TECHNICAL SUPPORT SERVICES 83
6.2.3.1 Need for continuous technical support to propel segment growth 83
6.2.4 TRIAL DESIGN AND CONSULTING SERVICES 85
6.2.4.1 High R&D spending and favorable government initiatives for clinical trials to fuel market growth 85
6.3 SOFTWARE 87
6.3.1 NEED FOR HIGHLY EFFICIENT AND COST-EFFECTIVE CLINICAL OPERATIONS SOFTWARE TO FAVOR MARKET GROWTH 87
?
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY 90
7.1 INTRODUCTION 91
7.2 COMPUTED TOMOGRAPHY 91
7.2.1 HIGHER CONTRAST IMAGE AND QUICKER TEST RESULTS TO AUGMENT SEGMENT GROWTH 91
7.3 MAGNETIC RESONANCE IMAGING 94
7.3.1 GREATER OBJECTIVITY, SENSITIVITY, AND REPRODUCIBILITY TO PROPEL MARKET GROWTH 94
7.4 ULTRASOUND 96
7.4.1 COST-EFFECTIVENESS AND EASE OF USE TO FUEL MARKET GROWTH 96
7.5 POSITRON EMISSION TOMOGRAPHY 99
7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS IN HUMANS AND ANIMALS TO BOOST MARKET GROWTH 99
7.6 X-RAY 101
7.6.1 LOW SCANNING COST AND TECHNOLOGICAL ADVANCEMENTS TO FAVOR MARKET GROWTH 101
7.7 OTHER MODALITIES 103
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 106
8.1 INTRODUCTION 107
8.2 ONCOLOGY 107
8.2.1 GROWING INCIDENCE OF CANCER AND INCREASING R&D INVESTMENTS BY PHARMA COMPANIES TO AID MARKET GROWTH 107
8.3 INFECTIOUS DISEASES 110
8.3.1 RISING DRUG DISCOVERY ACTIVITY AND GROWING DEMAND FOR THERAPEUTICS TO SPUR MARKET GROWTH 110
8.4 NEUROLOGY 112
8.4.1 HIGH RESEARCH INVESTMENTS FOR NEUROLOGIC DRUGS TO PROPEL MARKET GROWTH 112
8.5 CARDIOVASCULAR SYSTEM DISORDERS 114
8.5.1 HIGH MORTALITY RATE AND COMPLEX CLINICAL TRIAL PROCEDURES TO AUGMENT MARKET GROWTH 114
8.6 ENDOCRINOLOGY 116
8.6.1 RISING PREVALENCE OF DIABETES AND INCREASING RESEARCH FUNDING FOR METABOLIC DISORDERS TO DRIVE MARKET 116
8.7 IMMUNOLOGICAL DISORDERS 119
8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH 119
8.8 OTHER THERAPEUTIC AREAS 121
?
9 CLINICAL TRIAL IMAGING MARKET, BY END USER 124
9.1 INTRODUCTION 125
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 125
9.2.1 HIGH R&D BUDGETS AND FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT MARKET GROWTH 125
9.3 MEDICAL DEVICE MANUFACTURERS 129
9.3.1 HIGH SPENDING ON R&D AND CLINICAL TRIALS TO SUPPORT MARKET GROWTH 129
9.4 CONTRACT RESEARCH ORGANIZATIONS 131
9.4.1 INCREASING TREND OF OUTSOURCING AND GROWING PATIENT POPULATION IN EMERGING ECONOMIES TO AID MARKET GROWTH 131
9.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 134
9.5.1 RISING RESEARCH FUNDING AND INCREASING GOVERNMENT SUPPORT FOR CLINICAL TRIALS TO BOOST MARKET GROWTH 134
9.6 OTHER END USERS 136
10 CLINICAL TRIAL IMAGING MARKET, BY REGION 139
10.1 INTRODUCTION 140
10.2 NORTH AMERICA 140
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 143
10.2.2 US 144
10.2.2.1 US to dominate North American clinical trial imaging market during study period 144
10.2.3 CANADA 147
10.2.3.1 Increase in per capita healthcare spending to augment market growth 147
10.3 EUROPE 149
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 152
10.3.2 GERMANY 153
10.3.2.1 Strong medical technology infrastructure and increased funding for biomedical research to augment market growth 153
10.3.3 UK 155
10.3.3.1 Increased R&D investments and high per capita healthcare expenditure to augment market growth 155
10.3.4 FRANCE 157
10.3.4.1 Developed generics market and favorable government healthcare policies to support market growth 157
10.3.5 ITALY 159
10.3.5.1 Increasing number of drug approvals and rising investments in clinical trials to drive market 159
10.3.6 SPAIN 161
10.3.6.1 Increased biologics production and improved healthcare infrastructure to aid market growth 161
10.3.7 REST OF EUROPE 164
?
10.4 ASIA PACIFIC 167
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 170
10.4.2 CHINA 171
10.4.2.1 Favorable government regulations and presence of large target patient population to boost market growth 171
10.4.3 JAPAN 173
10.4.3.1 Increasing geriatric population and rising healthcare expenditure to favor market growth 173
10.4.4 INDIA 176
10.4.4.1 Increased government focus on developing advanced healthcare infrastructure to augment market growth 176
10.4.5 REST OF ASIA PACIFIC 178
10.5 LATIN AMERICA 181
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 183
10.5.2 BRAZIL 184
10.5.2.1 Increasing investments in biopharmaceutical research to propel market growth 184
10.5.3 MEXICO 186
10.5.3.1 Developed pharmaceutical and biotechnology industry and high demand for personalized medicines to aid market growth 186
10.5.4 REST OF LATIN AMERICA 188
10.6 MIDDLE EAST & AFRICA 191
10.6.1 INCREASED FUNDING AND COLLABORATIONS IN RESEARCH SECTOR TO DRIVE MARKET 191
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 193
10.7 GCC COUNTRIES 194
10.7.1 INCREASING RESEARCH ACTIVITIES AND GROWING BIOTECHNOLOGY INDUSTRY TO SPUR MARKET GROWTH 194
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 197
11 COMPETITIVE LANDSCAPE 198
11.1 INTRODUCTION 198
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 198
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CLINICAL TRIAL IMAGING MARKET 198
11.3 REVENUE ANALYSIS, 2021–2023 199
11.4 MARKET SHARE ANALYSIS, 2023 200
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2023) 202
11.5.1 STARS 202
11.5.2 EMERGING LEADERS 202
11.5.3 PERVASIVE PLAYERS 202
11.5.4 PARTICIPANTS 202
?
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 203
11.5.5.1 Company footprint 203
11.5.5.2 Service & software footprint 204
11.5.5.3 Therapeutic area footprint 204
11.5.5.4 Region footprint 204
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 205
11.6.1 PROGRESSIVE COMPANIES 205
11.6.2 RESPONSIVE COMPANIES 205
11.6.3 DYNAMIC COMPANIES 205
11.6.4 STARTING BLOCKS 205
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 206
11.7 COMPANY VALUATION AND FINANCIAL METRICS 207
11.8 COMPETITIVE SCENARIO 208
11.8.1 SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS 208
11.8.2 DEALS 209
12 COMPANY PROFILES 210
12.1 KEY PLAYERS 210
12.1.1 ICON PLC 210
12.1.1.1 Business overview 210
12.1.1.2 Services/Solutions offered 211
12.1.1.3 Recent developments 211
12.1.1.3.1 Solution launches 211
12.1.1.3.2 Deals 212
12.1.1.4 MnM view 212
12.1.1.4.1 Key strengths 212
12.1.1.4.2 Strategic choices 212
12.1.1.4.3 Weaknesses and competitive threats 213
12.1.2 MEDPACE 214
12.1.2.1 Business overview 214
12.1.2.2 Services/Solutions offered 215
12.1.2.3 MnM view 215
12.1.2.3.1 Key strengths 215
12.1.2.3.2 Strategic choices 215
12.1.2.3.3 Weaknesses and competitive threats 215
?
12.1.3 CLARIO 216
12.1.3.1 Business overview 216
12.1.3.2 Services/Solutions offered 216
12.1.3.3 Recent developments 217
12.1.3.3.1 Solution launches 217
12.1.3.3.2 Deals 217
12.1.3.4 MnM view 218
12.1.3.4.1 Key strengths 218
12.1.3.4.2 Strategic choices 218
12.1.3.4.3 Weaknesses and competitive threats 218
12.1.4 IXICO PLC 219
12.1.4.1 Business overview 219
12.1.4.2 Services/Solutions offered 220
12.1.4.3 Recent developments 221
12.1.4.3.1 Deals 221
12.1.4.3.2 Other developments 221
12.1.5 RESONANCE HEALTH LTD. 222
12.1.5.1 Business overview 222
12.1.5.2 Services/Solutions offered 223
12.1.5.3 Recent developments 224
12.1.5.3.1 Service launches and regulatory approvals 224
12.1.5.3.2 Deals 224
12.1.6 RADIANT SAGE 225
12.1.6.1 Business overview 225
12.1.6.2 Services/Solutions offered 225
12.1.7 WCG CLINICAL 226
12.1.7.1 Business overview 226
12.1.7.2 Services/Solutions offered 226
12.1.7.3 Recent developments 226
12.1.7.3.1 Deals 226
12.1.8 CARDIOVASCULAR IMAGING TECHNOLOGIES 227
12.1.8.1 Business overview 227
12.1.8.2 Services/Solutions offered 227
12.2 OTHER PLAYERS 228
12.2.1 MEDICAL METRICS, INC. 228
12.2.2 PRISM CLINICAL IMAGING 229
12.2.3 BOSTON IMAGING CORE LAB 230
12.2.4 ANAGRAM 4 CLINICAL TRIALS 231
12.2.5 VOIANT 231
?
12.2.6 CALYX 232
12.2.7 BIOSPECTIVE INC. 233
12.2.8 PROSCAN IMAGING 234
12.2.9 MICRON, INC. 235
12.2.10 IMAGING ENDPOINTS 236
12.2.11 PERSPECTUM 237
12.2.12 PHARMTRACE 237
12.2.13 NAVITAS LIFE SCIENCES 238
12.2.14 MEDIAN TECHNOLOGIES 238
12.2.15 INVICRO, LLC 239
12.2.16 IMAGE CORE LAB 239
12.2.17 IMAGE ANALYSIS GROUP (IAG) 240
13 APPENDIX 241
13.1 DISCUSSION GUIDE 241
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 245
13.3 CUSTOMIZATION OPTIONS 247
13.4 RELATED REPORTS 247
13.5 AUTHOR DETAILS 248



List of Figures

FIGURE 1 CLINICAL TRIAL IMAGING MARKET: SEGMENTS CONSIDERED 31
FIGURE 2 CLINICAL TRIAL IMAGING MARKET: YEARS CONSIDERED 32
FIGURE 3 CLINICAL TRIAL IMAGING MARKET: RESEARCH DESIGN 34
FIGURE 4 CLINICAL TRIAL IMAGING MARKET: KEY DATA FROM SECONDARY SOURCES 35
FIGURE 5 CLINICAL TRIAL IMAGING MARKET: KEY PRIMARY SOURCES
(DEMAND AND SUPPLY SIDES) 36
FIGURE 6 CLINICAL TRIAL IMAGING MARKET: KEY INSIGHTS FROM PRIMARIES 38
FIGURE 7 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 38
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION AND REGION 39
FIGURE 9 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 40
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
FIGURE 11 CLINICAL TRIAL IMAGING MARKET: TOP-DOWN APPROACH 41
FIGURE 12 DATA TRIANGULATION METHODOLOGY 42
FIGURE 13 CLINICAL TRIAL IMAGING MARKET: STUDY ASSUMPTIONS 43
FIGURE 14 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2024 VS. 2029 (USD MILLION) 45
FIGURE 15 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2024 VS. 2029 (USD MILLION) 46
FIGURE 16 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2024 VS. 2029 (USD MILLION) 46
FIGURE 17 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 47
FIGURE 18 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION) 48
FIGURE 19 INCREASE IN R&D SPENDING TO DRIVE MARKET GROWTH 49
FIGURE 20 SERVICES TO DOMINATE CLINICAL TRIAL IMAGING SERVICE & SOFTWARE MARKET IN 2029 49
FIGURE 21 COMPUTED TOMOGRAPHY TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 50
FIGURE 22 ONCOLOGY TO COMMAND LARGEST MARKET SHARE IN 2029 50
FIGURE 23 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE END-USER MARKET FROM 2024 TO 2029 51
FIGURE 24 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING STUDY PERIOD 51
FIGURE 25 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES 52
FIGURE 26 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2022) 53
FIGURE 27 PATENT APPLICATIONS FOR CLINICAL TRIAL IMAGING
(JANUARY 2013–DECEMBER 2023) 57
FIGURE 28 CLINICAL TRIAL IMAGING MARKET: VALUE CHAIN ANALYSIS 60
FIGURE 29 CLINICAL TRIAL IMAGING MARKET: SUPPLY CHAIN ANALYSIS 61
FIGURE 30 CLINICAL TRIAL IMAGING MARKET: ECOSYSTEM ANALYSIS 62
FIGURE 31 CLINICAL TRIAL IMAGING MARKET: PORTER’S FIVE FORCES ANALYSIS 63
FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL IMAGING SERVICES/SOLUTIONS 65
FIGURE 33 KEY BUYING CRITERIA FOR MAJOR END USERS 66
FIGURE 34 CLINICAL TRIAL IMAGING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 73
FIGURE 35 R&D INVESTMENTS IN PHARMACEUTICAL INDUSTRY, 2012–2026 (USD BILLION) 126
FIGURE 36 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 141
FIGURE 37 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 167
FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET (2021–2023) 200
FIGURE 39 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET (2023) 200
FIGURE 40 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 203
FIGURE 41 CLINICAL TRIAL IMAGING MARKET: COMPANY FOOTPRINT 203
FIGURE 42 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 206
FIGURE 43 EV/EBITDA OF KEY VENDORS 207
FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 208
FIGURE 45 ICON PLC: COMPANY SNAPSHOT 211
FIGURE 46 MEDPACE: COMPANY SNAPSHOT 214
FIGURE 47 IXICO PLC: COMPANY SNAPSHOT 219
FIGURE 48 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT 223

List of Tables

TABLE 1 CLINICAL TRIAL IMAGING MARKET: INCLUSIONS AND EXCLUSIONS 32
TABLE 2 CLINICAL TRIAL IMAGING MARKET: KEY DATA FROM PRIMARY SOURCES 37
TABLE 3 CLINICAL TRIAL IMAGING MARKET: RISK ASSESSMENT ANALYSIS 44
TABLE 4 INDICATIVE SELLING PRICE TREND FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021–2023 56
TABLE 5 CLINICAL TRIAL IMAGING MARKET: LIST OF KEY PATENTS JANUARY 2022–DECEMBER 2023 57
TABLE 6 IMPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY 2018–2022 (USD MILLION) 58
TABLE 7 EXPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY 2018–2022 (USD MILLION) 59
TABLE 8 IMPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY 2018–2022 (USD MILLION) 59
TABLE 9 EXPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY 2018–2022 (USD MILLION) 60
TABLE 10 CLINICAL TRIAL IMAGING MARKET: ROLE IN ECOSYSTEM 62
TABLE 11 CLINICAL TRIAL IMAGING MARKET: IMPACT OF PORTER’S FIVE FORCES 64
TABLE 12 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 66
TABLE 13 KEY BUYING CRITERIA FOR MAJOR END USERS 66
TABLE 14 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 67
TABLE 15 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 16 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 69
TABLE 17 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 70
TABLE 18 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 19 CLINICAL TRIAL IMAGING MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2023–DECEMBER 2024 71
TABLE 20 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 77
TABLE 21 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 77
TABLE 22 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION 2022–2029 (USD MILLION) 78
TABLE 23 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 78
TABLE 24 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY 2022–2029 (USD MILLION) 78
TABLE 25 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY 2022–2029 (USD MILLION) 79
TABLE 26 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 79
TABLE 27 OPERATIONAL IMAGING SERVICES MARKET, BY REGION 2022–2029 (USD MILLION) 80
TABLE 28 NORTH AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 80
TABLE 29 EUROPE: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY 2022–2029 (USD MILLION) 80
TABLE 30 ASIA PACIFIC: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY 2022–2029 (USD MILLION) 81
TABLE 31 LATIN AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY 2022–2029 (USD MILLION) 81
TABLE 32 READ ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 82
TABLE 33 NORTH AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY 2022–2029 (USD MILLION) 82
TABLE 34 EUROPE: READ ANALYSIS SERVICES MARKET, BY COUNTRY 2022–2029 (USD MILLION) 82
TABLE 35 ASIA PACIFIC: READ ANALYSIS SERVICES MARKET, BY COUNTRY 2022–2029 (USD MILLION) 83
TABLE 36 LATIN AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY 2022–2029 (USD MILLION) 83
TABLE 37 SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY REGION 2022–2029 (USD MILLION) 84
TABLE 38 NORTH AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET BY COUNTRY, 2022–2029 (USD MILLION) 84
TABLE 39 EUROPE: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 84
TABLE 40 ASIA PACIFIC: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET BY COUNTRY, 2022–2029 (USD MILLION) 85
TABLE 41 LATIN AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET BY COUNTRY, 2022–2029 (USD MILLION) 85
TABLE 42 TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY REGION 2022–2029 (USD MILLION) 86
TABLE 43 NORTH AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET BY COUNTRY, 2022–2029 (USD MILLION) 86
TABLE 44 EUROPE: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 86
TABLE 45 ASIA PACIFIC: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 87
TABLE 46 LATIN AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET BY COUNTRY, 2022–2029 (USD MILLION) 87
TABLE 47 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION 2022–2029 (USD MILLION) 88
TABLE 48 NORTH AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 88
TABLE 49 EUROPE: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY 2022–2029 (USD MILLION) 88
TABLE 50 ASIA PACIFIC: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY 2022–2029 (USD MILLION) 89
TABLE 51 LATIN AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 89
TABLE 52 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION) 91
TABLE 53 CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2022–2029 (USD MILLION) 92
TABLE 54 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 55 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY BY COUNTRY, 2022–2029 (USD MILLION) 93
TABLE 56 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION) 93
TABLE 57 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION) 93
TABLE 58 CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING BY REGION, 2022–2029 (USD MILLION) 94
TABLE 59 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 60 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 61 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 62 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION) 96
TABLE 63 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION 2022–2029 (USD MILLION) 97
TABLE 64 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND BY COUNTRY, 2022–2029 (USD MILLION) 97
TABLE 65 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 66 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 67 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 68 CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY BY REGION, 2022–2029 (USD MILLION) 99
TABLE 69 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 70 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 71 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 72 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 73 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION 2022–2029 (USD MILLION) 102
TABLE 74 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 75 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY 2022–2029 (USD MILLION) 102
TABLE 76 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY 2022–2029 (USD MILLION) 103
TABLE 77 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022–2029 (USD MILLION) 103
TABLE 78 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION 2022–2029 (USD MILLION) 104
TABLE 79 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 80 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 81 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 82 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 83 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 107
TABLE 84 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION 2022–2029 (USD MILLION) 108
TABLE 85 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 86 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY 2022–2029 (USD MILLION) 109
TABLE 87 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 88 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 89 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION) 110
TABLE 90 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 91 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 92 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES
BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 93 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES
BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 94 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION 2022–2029 (USD MILLION) 112
TABLE 95 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 96 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 97 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 98 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 99 CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2022–2029 (USD MILLION) 114
TABLE 100 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 101 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 102 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 103 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 104 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION 2022–2029 (USD MILLION) 117
TABLE 105 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 106 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 107 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 108 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 109 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 110 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 111 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 112 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 113 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 114 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION) 122
TABLE 115 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 116 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 117 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 118 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 119 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION) 125
TABLE 120 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 127
TABLE 121 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 122 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 123 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 124 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 125 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS BY REGION, 2022–2029 (USD MILLION) 129
TABLE 126 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 127 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 128 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 129 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 130 CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION) 132
TABLE 131 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 132 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 133 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 134 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 135 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION) 134
TABLE 136 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 137 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 138 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 139 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 140 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION 2022–2029 (USD MILLION) 136
TABLE 141 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 142 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 143 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 144 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 145 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION) 140
TABLE 146 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY 2022–2029 (USD MILLION) 141
TABLE 147 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION) 142
TABLE 148 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 142
TABLE 149 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 142
TABLE 150 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 143
TABLE 151 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 143
TABLE 152 NORTH AMERICA: KEY MACROINDICATORS 144
TABLE 153 US: LIST OF PRODUCT APPROVALS BY KEY PLAYERS, 2020–2023 144
TABLE 154 US: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 145
TABLE 155 US: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 145
TABLE 156 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION) 145
TABLE 157 US: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 146
TABLE 158 US: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION) 146
TABLE 159 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 147
TABLE 160 CANADA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 147
TABLE 161 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 148
TABLE 162 CANADA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 148
TABLE 163 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 149
TABLE 164 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY 2022–2029 (USD MILLION) 150
TABLE 165 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 150
TABLE 166 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 150
TABLE 167 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 151
TABLE 168 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 151
TABLE 169 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 152
TABLE 170 EUROPE: KEY MACROINDICATORS 152
TABLE 171 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 153
TABLE 172 GERMANY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 153
TABLE 173 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 154
TABLE 174 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 154
TABLE 175 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 155
TABLE 176 UK: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 155
TABLE 177 UK: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 156
TABLE 178 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION) 156
TABLE 179 UK: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 157
TABLE 180 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION) 157
TABLE 181 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 158
TABLE 182 FRANCE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 158
TABLE 183 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 158
TABLE 184 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 159
TABLE 185 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 159
TABLE 186 ITALY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 160
TABLE 187 ITALY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 160
TABLE 188 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 160
TABLE 189 ITALY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 161
TABLE 190 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 161
TABLE 191 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 162
TABLE 192 SPAIN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 162
TABLE 193 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 163
TABLE 194 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 163
TABLE 195 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 164
TABLE 196 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029(USD MILLION) 164
TABLE 197 REST OF EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 165
TABLE 198 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 165
TABLE 199 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 166
TABLE 200 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 166
TABLE 201 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY 2022–2029 (USD MILLION) 168
TABLE 202 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION) 168
TABLE 203 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 168
TABLE 204 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 169
TABLE 205 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 169
TABLE 206 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 170
TABLE 207 ASIA PACIFIC: KEY MACROINDICATORS 170
TABLE 208 CHINA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 171
TABLE 209 CHINA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 172
TABLE 210 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 172
TABLE 211 CHINA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 173
TABLE 212 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 173
TABLE 213 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 174
TABLE 214 JAPAN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 174
TABLE 215 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 175
TABLE 216 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 175
TABLE 217 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 176
TABLE 218 INDIA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 177
TABLE 219 INDIA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 177
TABLE 220 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 177
TABLE 221 INDIA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 178
TABLE 222 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 178
TABLE 223 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION) 179
TABLE 224 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 225 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 179
TABLE 226 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 180
TABLE 227 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 180
TABLE 228 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY 2022–2029 (USD MILLION) 181
TABLE 229 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION) 181
TABLE 230 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 182
TABLE 231 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 182
TABLE 232 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 183
TABLE 233 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 183
TABLE 234 LATIN AMERICA: KEY MACROINDICATORS 184
TABLE 235 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 184
TABLE 236 BRAZIL: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 185
TABLE 237 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 185
TABLE 238 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 186
TABLE 239 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 186
TABLE 240 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 2022–2029 (USD MILLION) 187
TABLE 241 MEXICO: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 187
TABLE 242 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 187
TABLE 243 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 188
TABLE 244 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 188
TABLE 245 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION) 189
TABLE 246 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 247 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION) 190
TABLE 248 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 190
TABLE 249 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION) 191
TABLE 250 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION) 192
TABLE 251 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 252 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 192
TABLE 253 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 193
TABLE 254 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 193
TABLE 255 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 194
TABLE 256 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION) 194
TABLE 257 GCC COUNTRIES: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 195
TABLE 258 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY MODALITY 2022–2029 (USD MILLION) 195
TABLE 259 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 196
TABLE 260 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY END USER 2022–2029 (USD MILLION) 196
TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET 198
TABLE 262 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION 201
TABLE 263 CLINICAL TRIAL IMAGING MARKET: SERVICE & SOFTWARE FOOTPRINT 204
TABLE 26